Initial data on NTLA-2001, which is a novel investigative intravenous agent that works to prevent development of cardiac transthyretin (ATTR) amyloidosis by targeting the TTR gene and TTR protein levels, were presented at this year’s American Heart Association’s Scientific Sessions in Chicago.
In an interview with The American Journal of Managed Care® at this year’s American Heart Association’s Scientific Sessions in Chicago, Douglas L. Mann, MD, professor of medicine at Washington University School of Medicine in St. Louis and editor-in-chief of JACC: Basic to Translational Science, discussed CRISPR/Cas9 editing findings following administration of NTLA-2001 among patients who have transthyretin amyloidosis with cardiomyopathy—a condition that can often lead to heart failure.
Transcript
Does the presence of COVID-19 make the need for this therapy more urgent?
What we found with COVID-19, if you have underlying heart disease, COVID makes it worse. So I think for people who do have far advanced disease, such as New York Heart class III and IV heart failure patients, if they got COVID, it would complicate the disease. Perhaps those people would be on ventilators more or have longer hospitalizations, or even have adverse outcomes such as death. I think COVID just takes everything that is bad with heart disease and makes it worse. So I would predict for the amyloid population—as we know in the heart failure population—it makes outcomes worse.
What are the next steps to study this therapy?
I think that the next steps would be to do a properly powered designed clinical trial, a phase 3 trial, to test it in more patients to look for the adverse effects, but also to try to achieve hard end points such as cardiovascular death reduction and hospitalization reduction. I would be stunned if they're not planning that trial now based on the successful results of their early phase 1 studies. I think it's a really encouraging therapy, and the nice part is is that you get sustained reduction of levels with 1 injection every 6 months. So I think from the patient standpoint, it's going to be really a nice therapy.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Study Suggests Walking 10K Steps Daily Improves QOL in Severe Hemophilia
April 12th 2024Among a small group of patients with severe hemophilia, researchers found that getting in more than 10,000 steps each day was linked to significant improvements in perceived physical health and quality of life (QOL).
Read More